Blis Technologies Limited is a biotechnology company that manufactures advanced probiotics for the mouth and throat.
Company founder Professor John Tagg is credited with developing and commercialising the world's first probiotic for the mouth and throat. Tagg's research found that with the right balance of good bacteria, people enjoy better oral and throat health, as well as more pleasant breath.
Blis products have been sold globally, with sales expanding across Europe, Asia and Australasia in recent years. Headquartered in Dunedin, Blis Technologies are publicly listed on the New Zealand Stock Exchange.
Video Blis Technologies
History
Professor John Tagg spent 30 years researching the effects of 'friendly bacteria', firstly at Melbourne University and later Monash. Tagg contracted rheumatic fever at age 12, and later decided, as a young microbiology student, to seek an effective way of countering the disease.
In August 2000, he left his academic position at the University of Otago to launch the Dunedin-based company.
Two years later the first oral probiotic - ThroatGuard containing BLISK12 - appeared on the shelves of New Zealand pharmacies. A wide variety of products have been subsequently developed, with many now sold internationally in lozenges, gum, power and other forms.
Maps Blis Technologies
Awards and Innovation
Blis Technologies hold the world-first patent for their beneficial strain of the oral bacteria, Streptococcus salivarius. This research breakthrough has led to several noteworthy acknowledgements, including the 2010 Frost & Sullivan award for Global Entrepreneurship.
The company was also acknowledged by multinational Deloitte as the Fastest Growing Mature Business in New Zealand for 2016.
Recent Developments
ThroatGuard was launched in May 2002, containing BLIS K12 which produces bacteriocins (natural anti-bacterial agents used to control the growth of undesirable bacteria). BLIS K12 is a specific strain of Strepctococcus salivarious - which promotes good bacteria and prevents disease. BLIS K12 is a patent-protected strain.
A secondary product containing BLIS K12 in a powder form suitable for children and infants, was developed and branded ToddlerProtect.
A third product was later rolled in 2006, TravelGuard, suitable for travelers exposed to airborne germs.
In September 2005, Blis announced the launch of FreshBreath, aimed with promoting and maintaining fresher breath. The product has properties which prevent the growth of bad bacteria, while also retain the good bacteria that generic mouthwash products consequently kill.
Blis Technologies introduced a new probiotic to the New Zealand market in October 2012, focused on fighting the bacteria associated with tooth decay and periodontal disease. The BLIS M18 (Streptococcis salivarius) strain was developed and launched into the market under the brand name HealthyTeeth. Several clinical trials found BLIS M18 to promote the health of the oral cavity, by continuously supporting and promoting the health of teeth and gums.
In 2011, Blis K12 received GRAS (generally recognised as safe) status from the United States Food and Drug Administration, enabling the probiotic to be used as a food additive.
References
Source of the article : Wikipedia
0 Comments